Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) — Cash Flow Reinvestment Rate

Latest as of December 2023: 16.27x

Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has a Cash Flow Reinvestment Rate of 16.27x as of December 2023, reinvesting CN¥602.32 Million (capex CN¥70.15 Million plus investments CN¥-532.17 Million) from operating cash flow of CN¥37.03 Million. Check Shandong Keyuan Pharmaceutical Co. Ltd. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

16.27x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥602.32 Million
Capex + Investments

Operating Cash Flow

CN¥37.03 Million
CNY

Capital Expenditures

CN¥70.15 Million
CNY

Shandong Keyuan Pharmaceutical Co. Ltd. A Cash Flow Reinvestment Rate (2021–2023)

Historical reinvestment intensity for Shandong Keyuan Pharmaceutical Co. Ltd. A across 3 annual periods. Explore 301281 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2023)

Year-by-year capital reinvestment analysis for Shandong Keyuan Pharmaceutical Co. Ltd. A. For live market cap and broader valuation context, see market cap of Shandong Keyuan Pharmaceutical Co. Ltd. .

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2023 16.27x CN¥602.32 Million CN¥37.03 Million CN¥70.15 Million ▲ +5958.1%
2022 0.27x CN¥31.11 Million CN¥115.86 Million CN¥31.11 Million ▼ -30.8%
2021 0.39x CN¥20.19 Million CN¥52.02 Million CN¥20.19 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow